125 related articles for article (PubMed ID: 31846841)
1. Upregulation of DPY30 promotes cell proliferation and predicts a poor prognosis in cholangiocarcinoma.
Hong ZF; Zhang WQ; Wang SJ; Li SY; Shang J; Liu F; Shen DY
Biomed Pharmacother; 2020 Mar; 123():109766. PubMed ID: 31846841
[TBL] [Abstract][Full Text] [Related]
2. DPY30 Promotes Proliferation and Cell Cycle Progression of Colorectal Cancer Cells via Mediating H3K4 Trimethylation.
Su WC; Mao XM; Li SY; Luo CY; Fan R; Jiang HF; Zhang LJ; Wang YT; Su GQ; Shen DY
Int J Med Sci; 2023; 20(7):901-917. PubMed ID: 37324189
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
4. MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.
Liao G; Liu X; Wu D; Duan F; Xie X; Wen S; Li Y; Li S
Aging (Albany NY); 2019 Jun; 11(11):3639-3649. PubMed ID: 31180332
[TBL] [Abstract][Full Text] [Related]
5. Roles of DPY30 in the Proliferation and Motility of Gastric Cancer Cells.
Lee YJ; Han ME; Baek SJ; Kim SY; Oh SO
PLoS One; 2015; 10(7):e0131863. PubMed ID: 26147337
[TBL] [Abstract][Full Text] [Related]
6. DPY30 promotes the growth and survival of osteosarcoma cell by regulating the PI3K/AKT signal pathway.
Cheng G; An F; Cao Z; Zheng M; Zhao Z; Wu H
Eur J Histochem; 2023 Jan; 67(1):. PubMed ID: 36546421
[TBL] [Abstract][Full Text] [Related]
7. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
8. The DPY30 subunit in SET1/MLL complexes regulates the proliferation and differentiation of hematopoietic progenitor cells.
Yang Z; Augustin J; Chang C; Hu J; Shah K; Chang CW; Townes T; Jiang H
Blood; 2014 Sep; 124(13):2025-33. PubMed ID: 25139354
[TBL] [Abstract][Full Text] [Related]
9. TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors.
He JC; Yao W; Wang JM; Schemmer P; Yang Y; Liu Y; Qian YW; Qi WP; Zhang J; Shen Q; Yang T
Oncotarget; 2016 Nov; 7(46):75441-75456. PubMed ID: 27705912
[TBL] [Abstract][Full Text] [Related]
10. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma.
Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Gao J; Cui Y; Zhong X
Sci Rep; 2018 Aug; 8(1):12176. PubMed ID: 30111807
[TBL] [Abstract][Full Text] [Related]
12. miR-378 serves as a prognostic biomarker in cholangiocarcinoma and promotes tumor proliferation, migration, and invasion.
Zhou Z; Ma J
Cancer Biomark; 2019; 24(2):173-181. PubMed ID: 30594918
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
[TBL] [Abstract][Full Text] [Related]
14. High glucose-ROS conditions enhance the progression in cholangiocarcinoma via upregulation of MAN2A2 and CHD8.
Thonsri U; Wongkham S; Wongkham C; Hino S; Nakao M; Roytrakul S; Koga T; Seubwai W
Cancer Sci; 2021 Jan; 112(1):254-264. PubMed ID: 33141432
[TBL] [Abstract][Full Text] [Related]
15. Forced overexpression of FBP1 inhibits proliferation and metastasis in cholangiocarcinoma cells via Wnt/β-catenin pathway.
Zhao W; Yang S; Chen J; Zhao J; Dong J
Life Sci; 2018 Oct; 210():224-234. PubMed ID: 30193944
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of KLHL21 prevents cholangiocarcinoma progression through regulating cell proliferation and motility, arresting cell cycle and reducing Erk activation.
Chen J; Song W; Du Y; Li Z; Xuan Z; Zhao L; Chen J; Zhao Y; Tuo B; Zheng S; Song P
Biochem Biophys Res Commun; 2018 May; 499(3):433-440. PubMed ID: 29574153
[TBL] [Abstract][Full Text] [Related]
17. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma.
Xu Y; Yao Y; Jiang X; Zhong X; Wang Z; Li C; Kang P; Leng K; Ji D; Li Z; Huang L; Qin W; Cui Y
J Exp Clin Cancer Res; 2018 Apr; 37(1):81. PubMed ID: 29642935
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition.
Xu Y; Wang Z; Jiang X; Cui Y
Biomed Pharmacother; 2017 Aug; 92():17-23. PubMed ID: 28528181
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
Tian F; Li D; Chen J; Liu W; Cai L; Li J; Jiang P; Liu Z; Zhao X; Guo F; Li X; Wang S
Eur J Cancer; 2013 May; 49(7):1771-80. PubMed ID: 23313142
[TBL] [Abstract][Full Text] [Related]
20. Enhanced expression of lncRNA TP73-AS1 predicts adverse phenotypes for cholangiocarcinoma and exerts oncogenic properties in vitro and in vivo.
Yao Y; Sun Y; Jiang Y; Qu L; Xu Y
Biomed Pharmacother; 2018 Oct; 106():260-266. PubMed ID: 29966969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
